AI assistant
Sending…
TALPHERA, INC. — Director's Dealing 2019
Mar 4, 2019
35181_dirs_2019-03-04_6a6313c1-410b-4e01-b45a-f4ae47322ae7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2019-02-28
Reporting Person: Hamel Lawrence G (Chief Development Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-02-28 | Common Stock | P | 3682 | $2.81 | Acquired | 78053 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 29795 | Indirect |
Footnotes
F1: Balance includes non-reportable acquisition of 3,682 shares of Common Stock through the Company's Employee Stock Purchase Plan.
More from TALPHERA, INC.
Interim / Quarterly Report
2026
May 13
Proxy Solicitation & Information Statement
2026
Apr 29
Director's Dealing
2026
Mar 26
Regulatory Filings
2026
Mar 23
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Feb 21
Director's Dealing
2026
Feb 21
Director's Dealing
2026
Feb 21
Director's Dealing
2026
Feb 21
Major Shareholding Notification
2026
Feb 17